Related Experiment Video

Updated: Jun 4, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity

Marianne D Sadar1

  • 1Department of Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada. msadar@bcgsc.ca

Cancer Research
|February 3, 2011
PubMed

Insights

Androgen ablation therapy for advanced prostate cancer often fails, leading to lethal castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) N-terminal domain (NTD) with drugs like EPI-001 shows promise for treating CRPC.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Advanced prostate cancer treatment relies on androgen ablation therapy, which is not curative.
  • The disease frequently returns as lethal castration-resistant prostate cancer (CRPC).
  • CRPC development is linked to continued androgen receptor (AR) transactivation.

Purpose of the Study:

  • To explore novel therapeutic strategies targeting the AR N-terminal domain (NTD).
  • To evaluate the potential of AR NTD-directed agents in CRPC treatment.
  • To identify promising drug candidates for clinical development.

Main Methods:

  • Investigated the role of the AR NTD as a therapeutic target.
  • Developed and characterized small molecules, peptides, and decoys targeting the AR NTD.
  • Assessed specificity, toxicity, and antitumor activity of drug candidates.

Main Results:

  • The AR NTD represents a critical vulnerability in AR activity.
  • EPI-001, a small molecule targeting the AR NTD, demonstrated specificity, low toxicity, and cytoreductive antitumor activity.
  • Other AR NTD-targeting agents like sintokamide peptides were also developed.

Conclusions:

  • Targeting the AR NTD offers a promising strategy for overcoming resistance to current therapies.
  • EPI-001 is a well-characterized and promising candidate for clinical development in CRPC.
  • Further research into AR NTD-directed therapies could lead to more effective treatments for advanced prostate cancer.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...